Iterum Therapeutics plc
ITRM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.04 | 0.00 | 0.01 |
| FCF Yield | -76.78% | -154.07% | -180.32% | -24.83% |
| EV / EBITDA | -2.59 | -1.11 | -0.48 | -0.81 |
| Quality | ||||
| ROIC | -45.54% | -378.61% | -52.65% | -30.66% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.08 | 1.02 | 0.42 | 0.17 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 31.95% | -112.26% | -16.55% | 70.84% |
| Safety | ||||
| Net Debt / EBITDA | -0.99 | -0.37 | -0.23 | -0.04 |
| Interest Coverage | 0.00 | 0.00 | -12.87 | -4.42 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -360.69 | -1,042.02 | -562.51 | 0.00 |